🔗 Share this article

As the United States continues making sweeping adjustments to its vaccine recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines in the global health crisis and has zeroed in on alleged deaths after COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities planned to announce radical revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US out of step with a large portion of the world with little proof for improved outcomes. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s CDER, the fifth individual to head the center this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood shot schedules in the US to become more similar to Denmark's approach, a country with nationalized medicine and a population roughly the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

The appointee has no apparent background in pharmaceutical research, regulation or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Previous heads of CBER would “understand legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that former directors who led the center have had.”

This division has an immense portfolio at the FDA, she pointed out.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and more, and each of these must be supervised,” she noted. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership aspect to the role, which manages over 5,000 personnel. “It’s a massive leadership role, if you execute it properly,” Woodcock added.

Official Statement and Controversial Programs

When asked about concerns about Høeg’s qualifications and whether this selection signifies more teamwork among FDA leaders on immunizations, a spokesperson said that the “inquiries are based on flawed presumptions”.

“Her experience aligns with the functions of her position,” the official stated, pointing to the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious rapid medication authorization process that apparently concerned her former heads. “How are these therapies being selected for this voucher program? Who makes the calls?” Dr. Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards laxer oversight of all drugs, with the exception of immunizations.”

Established History on Immunizations

Regarding vaccines, Høeg has a more documented, if troubling, history, some experts observe. She released a analysis using unverified crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new government included changing regulations for recently developed shots and discontinuing “non-essential” immunizations, she said after the election on a audio program. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the data in a extremely misleading, untruthful way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|